NGM·Healthcare·$260M·#199 / 520 in Healthcare
CHRS Coherus Oncology, Inc.
53SPECULATIVE
CATEGORY BREAKDOWN
GROWTH84
QUALITY58
STABILITY26
VALUATION64
GOVERNANCE51
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+59.8%
84
> 50% strong
Gross Margin
Revenue retained after direct costs
67.2%
96
> 50% strong
Cash Runway
Months of cash at current burn rate
8 months
18
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
66.1%
41
< 25% strong
Price / Sales
Market cap relative to trailing revenue
6.2x
64
< 3x strong
Rule of 40
Growth rate plus operating margin
-370
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
15.3%
76
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+29.3%
1
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE CHRS WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when CHRS's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.